Macquarie Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-47,900
Closed -$3.57M 1640
2025
Q2
$3.57M Sell
47,900
-582
-1% -$38.5K ﹤0.01% 1058
2025
Q1
$3.08M Buy
48,482
+3,147
+7% +$214K ﹤0.01% 1100
2024
Q4
$3.54M Sell
45,335
-585
-1% -$47K ﹤0.01% 1027
2024
Q3
$3.69M Buy
45,920
+4,396
+11% +$355K ﹤0.01% 1043
2024
Q2
$3.44M Sell
41,524
-3,428
-8% -$302K ﹤0.01% 1067
2024
Q1
$3.84M Buy
44,952
+6,927
+18% +$544K ﹤0.01% 1037
2023
Q4
$3.25M Buy
38,025
+5,530
+17% +$478K ﹤0.01% 1082
2023
Q3
$2.91M Buy
32,495
+634
+2% +$56.6K ﹤0.01% 1063
2023
Q2
$2.71M Buy
31,861
+1,887
+6% +$160K ﹤0.01% 1085
2023
Q1
$2.48M Buy
29,974
+2,226
+8% +$180K ﹤0.01% 1103
2022
Q4
$2.18M Sell
27,748
-12,852
-32% -$1.03M ﹤0.01% 1180
2022
Q3
$3.04M Sell
40,600
-5,418
-12% -$389K ﹤0.01% 1107
2022
Q2
$3M Buy
46,018
+51
+0.1% +$3.02K ﹤0.01% 1161
2022
Q1
$2.91K Buy
45,967
+1,412
+3% +$76.8K ﹤0.01% 1269
2021
Q4
$2.36M Buy
44,555
+1,039
+2% +$63.3K ﹤0.01% 1325
2021
Q3
$3.07M Buy
43,516
+5,071
+13% +$320K ﹤0.01% 1242
2021
Q2
$2.56M Buy
38,445
+3,242
+9% +$229K ﹤0.01% 1339
2021
Q1
$3.91M Buy
35,203
+32,379
+1,147% +$4.01M 0.01% 980
2020
Q4
$335K Hold
2,824
﹤0.01% 1535
2020
Q3
$246K Sell
2,824
-167,854
-98% -$14.7M ﹤0.01% 1558
2020
Q2
$15.3M Buy
170,678
+48,362
+40% +$4.88M 0.03% 537
2020
Q1
$12.2M Sell
122,316
-13,999
-10% -$1.52M 0.03% 518
2019
Q4
$15.7M Buy
136,315
+11,837
+10% +$1.43M 0.02% 569
2019
Q3
$15.7M Sell
124,478
-9,849
-7% -$1.25M 0.03% 509
2019
Q2
$16.2M Buy
134,327
+22,652
+20% +$2.23M 0.03% 506
2019
Q1
$9.77M Sell
111,675
-49,633
-31% -$4.51M 0.02% 625
2018
Q4
$16.1M Sell
161,308
-2,501
-2% -$263K 0.03% 479
2018
Q3
$18.8M Sell
163,809
-363,769
-69% -$37.7M 0.03% 498
2018
Q2
$47.3M Sell
527,578
-97,757
-16% -$8.26M 0.08% 253
2018
Q1
$45.7M Sell
625,335
-51,815
-8% -$3.56M 0.08% 248
2017
Q4
$39.3M Sell
677,150
-5,921
-0.9% -$312K 0.07% 283
2017
Q3
$30.6M Buy
683,071
+54,485
+9% +$2.26M 0.06% 354
2017
Q2
$24.8M Buy
628,586
+19,158
+3% +$787K 0.05% 393
2017
Q1
$24.7M Buy
609,428
+15,593
+3% +$609K 0.04% 404
2016
Q4
$23.9M Sell
593,835
-9,943
-2% -$375K 0.05% 384
2016
Q3
$21.9M Sell
603,778
-610,566
-50% -$21M 0.04% 386
2016
Q2
$35.2M Buy
1,214,344
+494,483
+69% +$14.9M 0.03% 413
2016
Q1
$25.2M Sell
719,861
-280,823
-28% -$9.07M 0.05% 294
2015
Q4
$32.3M Buy
1,000,684
+22,365
+2% +$725K 0.07% 251
2015
Q3
$31.6M Buy
978,319
+17,910
+2% +$674K 0.07% 259
2015
Q2
$39.7M Buy
960,409
+4,955
+0.5% +$209K 0.08% 233
2015
Q1
$42.9M Buy
955,454
+202,244
+27% +$8.45M 0.08% 236
2014
Q4
$28.2M Buy
753,210
+127,912
+20% +$4.69M 0.06% 311
2014
Q3
$21.8M Buy
625,298
+46
+0% +$1.64K 0.05% 356
2014
Q2
$22.1M Sell
625,252
-56,082
-8% -$1.87M 0.05% 341
2014
Q1
$22.2M Sell
681,334
-155,812
-19% -$5.95M 0.04% 321
2013
Q4
$35.3M Buy
837,146
+124,232
+17% +$5.11M 0.06% 222
2013
Q3
$28.4M Buy
712,914
+8,259
+1% +$347K 0.06% 264
2013
Q2
$29.1M Buy
+704,655
New +$28.5M 0.06% 237

Other funds holding HAE

Macquarie Group's HAE Position: Q3 2025 in Review

Macquarie Group sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 47,900 shares — an estimated $3.57M sold.

Macquarie Group first reported a position in HAE in Q2 2013 and held it in 49 quarters. The position peaked at $47.3M in Q2 2018. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • Macquarie Group reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • Macquarie Group sold 47,900 Haemonetics shares in Q3 2025, an estimated $3.57M.
  • Macquarie Group first reported a position in Haemonetics in Q2 2013 and held it in 49 quarters.
  • Macquarie Group's Haemonetics position peaked at $47.3M in Q2 2018.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on Macquarie Group's 13F filing for Q3 2025, filed 13 Nov 2025.